Sanofi $SNY Shares Acquired by First Trust Advisors LP

First Trust Advisors LP lifted its position in shares of Sanofi (NASDAQ:SNY) by 2.4% in the 1st quarter, Holdings Channel.com reports. The firm owned 767,835 shares of the company’s stock after purchasing an additional 17,880 shares during the period. First Trust Advisors LP’s holdings in Sanofi were worth $36,994,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Advisory Services Network LLC raised its stake in Sanofi by 1.4% in the third quarter. Advisory Services Network LLC now owns 15,733 shares of the company’s stock valued at $743,000 after buying an additional 210 shares in the last quarter. Savant Capital LLC increased its holdings in shares of Sanofi by 2.7% in the 4th quarter. Savant Capital LLC now owns 8,623 shares of the company’s stock valued at $418,000 after acquiring an additional 225 shares during the last quarter. Wesbanco Bank Inc. increased its holdings in shares of Sanofi by 4.9% in the 4th quarter. Wesbanco Bank Inc. now owns 4,927 shares of the company’s stock valued at $239,000 after acquiring an additional 230 shares during the last quarter. IFG Advisory LLC raised its position in shares of Sanofi by 2.7% during the 4th quarter. IFG Advisory LLC now owns 9,213 shares of the company’s stock worth $446,000 after acquiring an additional 244 shares in the last quarter. Finally, Cohen Investment Advisors LLC raised its position in shares of Sanofi by 2.9% during the 1st quarter. Cohen Investment Advisors LLC now owns 9,480 shares of the company’s stock worth $457,000 after acquiring an additional 263 shares in the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Sanofi Stock Up 1.5%

SNY opened at $44.00 on Tuesday. The business has a 50 day moving average price of $43.45 and a two-hundred day moving average price of $45.31. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17. The company has a market cap of $106.67 billion, a PE ratio of 12.29, a P/E/G ratio of 1.10 and a beta of 0.34. Sanofi has a 52 week low of $40.89 and a 52 week high of $52.68.

Wall Street Analysts Forecast Growth

SNY has been the subject of a number of research analyst reports. Morgan Stanley set a $49.00 price target on Sanofi in a report on Wednesday, July 8th. Weiss Ratings raised shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Argus upgraded shares of Sanofi to a “strong-buy” rating in a research report on Monday, April 27th. BNP Paribas Exane cut shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 target price for the company. in a report on Monday, April 20th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Sanofi in a research report on Monday, April 13th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, Sanofi presently has an average rating of “Hold” and an average target price of $49.50.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.